About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

370533 studies
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
This website is for US healthcare professionals

Log In to Bolder Science


Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 04/16/2021.
  • Activity of IMiD® Agents in Multiple Myeloma

    The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.


    The IMiD agents, lenalidomide and pomalidomide, have immunomodulatory properties that have been demonstrated in preclinical studies.1-4 IMiD agents have been found to increase activation and proliferation of T cells, production of IL-2, and activity of CD8+ effector T cells.1-3 Stimulation and expression of natural killer (NK) cells, NK cell–mediated lysis via antibody-dependent cell-mediated cytotoxicity, and direct NK cell–mediated killing were also enhanced by IMiD agents.2,4 These data and others have led Celgene to evaluate the role of lenalidomide and pomalidomide in combination with various agents in multiple myeloma.

    In addition to immunomodulatory properties, IMiD agents are hypothesized to have multiple mechanisms of action, including tumoricidal and antiangiogenic activity.5

    Preclinical studies demonstrated increased anti-myeloma activity of IMiD agents in combination with dexamethasone and certain proteasome inhibitors and monoclonal antibodies.10-18

    BORT, bortezomib; DARA, daratumumab; DEX, dexamethasone; ELO, elotuzumab; LEN, lenalidomide; MRZ, marizomib; OPZ, oprozomib; POM, pomalidomide.

    View Related Molecules


    1. Gandhi AK, et al. Br J Haematol. 2014;164:811-821. PMID: 24328678
    2. Sehgal K, et al. Blood. 2015;125:4042-4051. PMID: 25869284
    3. Galustian C, et al. Expert Opin Biol Ther. 2004;4:1963-1970. PMID: 15571458
    4. Lapalombella R, et al. Blood. 2008;112:5180-5189. PMID: 18772452
    5. Quach H, et al. Leukemia. 2010;24:22-32. PMID: 19907437
    6. Lu G, et al. Science. 2014;343:305-309. PMID: 24292623
    7. Lopez-Girona A, et al. Leukemia. 2012;26:2326-2335. PMID: 22552008
    8. Kotla V, et al. J Hematol Oncol. 2009;12;2:36. PMID: 19674465
    9. Borrello I. Leuk Res. 2012;36:S3-S12. PMID: 23176722
    10. Imnovid (pomalidomide) [summary of product characteristics]. Uxbridge, UK: Celgene Europe; 2016.
    11. Rychak E, et al. Br J Haematol. 2016;172:889-901. PMID: 26914976
    12. Gandhi AK, et al. Curr Cancer Drug Targets. 2010;10:155-167. PMID: 20088798
    13. Celgene. Data on file (Report 8769-001).
    14. Chauhan D, et al. Blood. 2010;116:4906-4915. PMID: 20805366
    15. Das DS, et al. Br J Haematol. 2015;171:798-812. PMID: 26456076
    16. van der Veer MS, et al. Haematologica. 2011;96:284-290. PMID: 21109694
    17. Nijhof IS, et al. Clin Cancer Res. 2015;21:2802-2810. PMID: 25398450
    18. Boxhammer R, et al. Poster presented at ASCO 2015 [abstract 8588].